Top View
- Direct-Acting Antivirals
- Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
- Technology and Market Landscape for Hepatitis C Medicines
- JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 Or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1 - Zeuzem - - Hepat
- JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 Or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OM
- Press Release, 23 September 2016 Updated Interim Phase Iia Data Demonstrate That the Combination of Simeprevir, Odalasvir and AL
- The Challenge of Treating Children with Hepatitis C Virus Infection Giuseppe Indolfi1, Claire Thorne2, Manal H. El Sayed3, Carlo
- HCV Pipeline: Daas and Diagnostics in the Pangenotypic Era
- INN-Nimet 1 27.11.2018 a Abacavir Abacavirum Abakaviiri Abagovomab
- Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir And/Or Simeprevir
- Targeting Allosteric Pockets of SARS-Cov-2 Main Protease Mpro
- New Therapies for Hepatitis C Virus Infection
- Remdesivir from Wikipedia, the Free Encyclopedia
- COVID User's Guide (Updated: 14/12/2020)
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
- Dinesh and Boura-MS
- Wednesday, November 9, 2016 4 P.M
- An Alternative Research and Development Strategy to Deliver Affordable Treatments for Hepatitis C Patients: the Drugs
- Medication Coverage Policy
- The Importance of Resistance to Direct Antiviral Drugs in HCV Infection in Clinical Practice
- 209394Orig1s000